Autologous hematopoietic cell transplantation (AHCT) is a standard of care in multiple myeloma (MM) patients aged o65 years. To understand age-related trends in utilisation and outcome of AHCT, we analysed 53 675 MM patients who underwent a first AHCT in 31 European countries between 1991 and 2010. The number of patients undergoing AHCT increased for all age groups ( o40, 40-49, 50-59, 60-64, 65-69 In the 1980s, ground-breaking studies identified high-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) as an effective treatment option.
INRODUCTION
Multiple myeloma (MM) accounts for 10-13% of haematological malignancies and has a median age at diagnosis of 65-70 years. [1] [2] [3] [4] In the 1980s, ground-breaking studies identified high-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) as an effective treatment option. [5] [6] [7] [8] [9] [10] Subsequently, two randomised trials in patients under the age of 65 years demonstrated the superiority of high-dose chemotherapy and AHCT over standard chemotherapy. 11, 12 AHCT has also been shown to be feasible in selected older patients. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, intermediate-dose melphalan followed by AHCT was inferior to the combination of standard-dose melphalan with prednisolone and thalidomide in patients aged 65-75 years in the randomised IFM99-06 trial. 23 Consequently, AHCT has not been recommended as a standard of care for MM patients who are ⩾ 65 years of age. [24] [25] [26] [27] Large single-centre and population-based studies conducted in the US and in Europe have shown that survival of MM patients has improved considerably in recent years compared with past decades. [28] [29] [30] [31] [32] [33] [34] However, improvements in survival were predominantly seen in younger patients, with the exception of very recent US-based studies. [28] [29] [30] [31] [32] [33] [34] The reasons for these trends are not fully understood. Although some studies attributed improvements in survival to the introduction of drugs with novel mechanisms of action ('novel agents'), others associated better survival predominantly with AHCT, or trial participation. [28] [29] [30] [31] [32] [33] [34] AHCT is an intensive and costly procedure. On the other hand, AHCT can result in prolonged periods of therapy-free time that decrease the need for other economically challenging therapies. Hence, it is of clinical and economic importance to understand trends in utilisation and outcome of AHCT for MM. Given that most MM patients are 465 years, the cutoff age from which AHCT is not generally recommended, it is of particular relevance to consider these trends in relation to patient age. We therefore analysed first AHCT for MM in Europe that were reported to the European Society for Blood and Marrow Transplantation (EBMT) over a 20-year time period.
PATIENTS AND METHODS

The EBMT Registry
The EBMT is a nonprofit organisation that was established in 1974 and maintains a patient database known as the EBMT Registry, which encompasses data on hematopoietic cell transplant (HCT) procedures for all indications. The EBMT has a single centralised database where all the data requested through the standard data-collection forms are stored. The data are submitted when 100 days have elapsed from the date of transplant, or when the patient dies, whichever comes first. Follow-up is otherwise indefinite. All EBMT member centres need to forward these data to retain full membership. The data are stored in an SQL Server database, housed in the Leiden University Medical Centre, Leiden, The Netherlands. All centres inside and outside the European Union must obtain informed consent from their patients before the data can be submitted to the EBMT. Informed consent to data utilisation was obtained as previously described. 35 
Patients
Patients included in this study were reported to the EBMT Registry for undergoing a first AHCT for treatment of MM in a European country (including Turkey) between 01 January 1991 and 31 December 2010. Thus, patients were not included if they had a prior allogeneic HCT, or had their first AHCT for a disease other than MM. Patients were grouped into four 5-year calendar periods by time of first AHCT (1991-1995, 1996-2000, 2001-2005, and 2006-2010) and into six age groups based on their age at the time of AHCT ( o40, 40-49, 50-59, 60-64, 65-69 and ⩾ 70 years).
Statistical analysis
OS was calculated using the Kaplan-Meier method. OS was measured in months and defined as the time from the date of AHCT until date of death or last follow-up. Variables included in a proportional hazards regression analysis were age group, calendar period, gender, remission status at AHCT and disease duration before AHCT. Remission status was defined as previously described. 36, 37 RESULTS A total of 53 675 patients from 31 countries and 497 centres was reported to the EBMT for undergoing a first AHCT for treatment of MM between 1991 and 2010. The number of patients undergoing a first AHCT increased throughout all four calendar periods ( The absolute number of patients undergoing a first AHCT for MM increased for all age groups throughout the observation period ( Table 2 ). The highest proportional increase over time was observed for patients aged 65-69 years and ⩾ 70 years. These two age groups together accounted for 3% of AHCTs performed in 1991-1995 and for 18.8% of AHCTs performed in 2006-2010. Age groups showed small but statistically significant differences in gender distribution and remission status at AHCT, with a higher proportion of male patients and patients transplanted in 4PR in the younger age groups ( Table 2 ). The proportion of patients who underwent AHCT within 1 year from diagnosis decreased moderately with increasing age, from 78.5% in patients o 40 years to 70.8% in those aged ⩾ 70 years ( Table 2 ). Utilisation of early second AHCT ⩽ 6 months after the first transplant, which generally indicates a tandem-AHCT approach, was uncommon in 1991-1995 and peaked in 2001-2005 in all age groups. Although early second AHCTs were used less in 2006-2010 in all age groups, patients aged ⩾ 70 years showed the smallest decrease and represented the age group with the highest rate of early second transplants in this calendar period (Table 2) .
Survival rates after AHCT increased for all age groups from 1991-1995 to 2006-2010. Only two patients aged ⩾ 70 years underwent AHCT in 1991-1995 and died after 10 and 16 months, respectively, from progressive disease. We observed considerable differences between age groups in the changes of 2-year and 5-year survival after AHCT (Table 3 and Figure 1 ). The greatest improvement in 2-year survival was observed in patients aged 65-69 years (27.6%; from 55.3% in 1991-1995 to 82.9% in 2006-2010). The improvement in 2-year survival progressively decreased with every age bracket and was smallest in patients aged o 40 years The improvement in 5-year survival (Table 3 and Figure 1 ) was most pronounced in patients aged 60-64 years (26%; from 32. Abbreviations: AHCT = autologous hematopoietic cell transplantation; CI = confidence interval; NA = not applicable. a n = 2, death from progressive disease at 10 and 16 months, respectively. Over the entire observation period, factors associated with survival after AHCT in a proportional hazards regression analysis were patient age, calendar period, remission status at AHCT, gender and time between diagnosis and AHCT ( Table 4 ). The relative risk of death increased progressively for every age bracket compared with the youngest patient group (o 40 years). When compared with AHCTs performed in 1991-1995, the risk of dying decreased in every subsequent 5-year calendar period. Compared with AHCT in 4PR, the relative risk of death was also higher in patients undergoing AHCT in PR and particularly in o PR. Female patients were associated with a slightly but significantly reduced risk of death compared with male patients. The risk of death was slightly but significantly higher in patients who underwent AHCT ⩾ 12 months after diagnosis compared with patients who were autografted o 12 months after diagnosis. All-cause mortality at day-100 after AHCT was generally lower in younger patients and in more recent calendar periods (Table 5 ). In the most recent calendar period, all-cause mortality at day 100 ranged between 0.7 and 2.4%, representing a 450% improvement compared with the first observation period across all age groups.
21.2% in 1991-1995 (between patients
DISCUSSION
There are three key findings in the present study. First, utilisation of AHCT for MM in Europe continued to increase in recent years, and increased predominantly in older patients. Second, survival after AHCT improved more in older than in younger patients. Third, early deaths after AHCT decreased to very low levels in all age groups.
Our findings demonstrate that the use of AHCT for MM continued to increase in Europe in recent years, and increased particularly in older patients. These observations are compatible with those reported by the Centre for International Blood and Marrow Transplant Research for the US and Canada. 38, 39 Costa et al. 39 found that the number of AHCTs performed exceeded new MM cases in all age categories between 1995 and 2010, whereas the median age at AHCT increased from 54 to 59 years. McCarthy et al. 38 showed that the rate of AHCT for MM increased almost fivefold between 1994 and 2005. Together with these data from the US and Canada, the European data presented here indicate that, rather than supplanting AHCT, availability of novel agents has Figure 1 . OS after AHCT in patients with MM by age group and calendar period. Abbreviations: AHCT = autologous hematopoietic cell transplantation; CI = confidence interval; RR = relative risk.
Age and autologous transplantation in myeloma HW Auner et al contributed to a further increase in the utilisation of AHCT in recent years. One possible explanation for this is that more patients were able to proceed to AHCT, because induction therapy with novel agents resulted in better responses and fewer treatment failures. This view is compatible with our observation that significantly more patients underwent AHCT in 4PR in 2006-2010 compared with previous calendar periods. However, as the EBMT database does not consistently record pre-and posttransplant treatment, we were unable to formally test the impact of novel drugs on utilisation, or outcome, of AHCT in recent years. Another major finding of this study is that survival after AHCT improved considerably more in older than in younger patients, resulting in a substantial narrowing of the gap in post-transplant survival between age groups in recent years. In particular, the 2-year survival after AHCT was similar for all age groups in the most recent calendar period, with a 2-year post-transplant survival of 480% even in patients aged ⩾ 70 years. These observations are compatible with those reported by the Centre for International Blood and Marrow Transplant Research, who observed an adjusted 2-year survival rate of 84% for all patients transplanted in 2005-2010. 39 In contrast to the European data presented here, the Centre for International Blood and Marrow Transplant Research did not find a reduced risk of death after AHCTs performed in 2005-2010 compared with 2000-2004. 39 However, the risk of dying in the most recent periods was lower than in 1995-1999, confirming earlier findings on patients transplanted between 1995 and 2005. 38, 39 The EBMT data presented here provide evidence that post-transplant survival continued to improve in the most recent calendar period in the context of European healthcare systems and approaches to the treatment of MM. Furthermore, the data show for the first time that posttransplant survival has increased considerably more in older than in younger patients. The observations therefore have important clinical and economic implications, given that AHCT is not generally considered a standard of care in MM patients aged ⩾ 65 years. [24] [25] [26] [27] This cutoff age is largely based on the findings of the IFM99-06 trial, in which intermediate-dose melphalan followed by AHCT was inferior to melphalan-prednisolone-thalidomide in patients aged 65-75 years. 23 However, several studies have shown that AHCT is feasible, and can be an effective treatment option, in selected elderly MM patients. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] In particular, it is worth considering a recent study from the Mayo Clinic in which AHCT was associated with improved survival only in patients aged 465 years, not in patients aged ⩽ 65 years. The data presented here show that, although age was a risk factor for death throughout the observation period, this was not limited to the oldest patients but applied to all age groups when compared with the very youngest patients. Similarly, all-cause mortality at day 100 after AHCT was higher in older than in younger patients throughout the study period, but without a clear cutoff between age groups. In fact, allcause day-100 mortality was o2.5% even in patients aged ⩾ 70 years in the most recent calendar period. This finding is relevant as it indicates that treatment-related mortality across transplant centres is low in selected older patients. Our data therefore highlight the arbitrary nature of the 65-year cutoff that is commonly used to recommend AHCT as a standard of care. Another relevant finding of this study is that 5-year survival of patients aged o 40 and 40-49 years appears to have decreased in recent years. Although the lack of information on pre-and posttransplant treatment regimens precludes the identification of the causes for the development from this study, the findings warrant a close follow-up of the data.
It is important to note that we found male patients to be associated with an increased risk of death after AHCT. To our knowledge this is the first time that a gender-specific effect on survival after AHCT for MM has been observed. However, the finding is compatible with the shorter survival in male myeloma patients reported in a population-based study from Sweden that included transplanted and nontransplanted patients. 30 Our findings therefore highlight the need to investigate if gender disparity in outcomes of MM treatment is related to disease characteristics, treatment regimens or gender-specific comorbidities.
Registry studies are characterised by a number of benefits and limitations. 40 Key limitations of this study include the lack of prognostic markers and details regarding treatment before or after AHCT, including maintenance treatments. However, a skewed representation of prognostic factors is unlikely given the large number of patients included. Furthermore, the study included only patients who underwent AHCT. The findings therefore only apply to a selected population and cannot address a comparison of AHCT with nontransplant treatments. It is worth noting that selection of MM patients for AHCT is not limited to older patients. A Dutch population-based study showed that only 36% of patients aged ⩽ 65 years who were diagnosed with MM in 2001-2005 underwent AHCT. 32 In a recent study by the Mayo clinic, 56% of patients aged ⩽ 65 years who were diagnosed with MM in 2001-2010 underwent AHCT, compared with 21% of patients aged 465 years. 41 It is an important strength of this investigation that it included an unprecedentedly large number of MM patients, thereby allowing statistically well-powered subgroup analyses. Furthermore, transplants were performed at almost 500 centres in 31 nations. Thus, the study provides a representative and realistic view of the trends in both utilisation and outcome of AHCT for MM in Europe, particularly with regards to patient age. The results demonstrate for the first time that the number of patients who undergo AHCT for the treatment of MM across Europe increased substantially in recent years. The data also show a substantial increase in the proportion of older patients amongst Abbreviation: CI = confidence interval a n = 2, death from progressive disease at 10 and 16 months, respectively.
those who are selected for AHCT, and demonstrate that AHCT has become safe for selected patients of all age groups. Moreover, the findings demonstrate that post-transplant survival has improved more in older than in younger patients. Although the results from this study do not allow the conclusion that AHCT itself has improved the outcome of MM patients, they demonstrate that outcomes have improved for patients who are selected for AHCT, and have improved more for older than younger patients. It is likely that this improvement has resulted from the combined effects of novel therapies and AHCT. Further studies now need to investigate the optimal selection of patients at different ages for, and timing of, AHCT in the context of novel therapies.
